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Abstract
Vaccine-induced immunity depends on long-lived plasma cells (LLPCs) that maintain anti-
body levels. A recent mouse study showed that Plasmodium chaubaudi infection reduced
pre-existing influenza-specific antibodies—raising concerns that malaria may compromise
pre-existing vaccine responses. We extended these findings to P. yoelii infection, observing
decreases in antibodies to model antigens in inbred mice and to influenza in outbred mice,
associated with LLPC depletion and increased susceptibility to influenza rechallenge. We
investigated the implications of these findings in Malian children by measuring vaccine-spe-
cific IgG (tetanus, measles, hepatitis B) before and after the malaria-free 6-month dry sea-
son, 10 days after the first malaria episode of the malaria season, and after the subsequent
dry season. On average, vaccine-specific IgG did not decrease following acute malaria.
However, in some children malaria was associated with an accelerated decline in vaccine-
specific IgG, underscoring the need to further investigate the impact of malaria on pre-exist-
ing vaccine-specific antibodies.
Introduction
Since the Expanded Program on Immunization was implemented in the mid-1970s [1] there
has been remarkable progress toward reducing the morbidity and mortality associated with
vaccine-preventable diseases [2], yet ~20% of deaths in children under 5 years of age remain
vaccine-preventable [3]. In lower-income regions, this is largely attributable to inadequate
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immunization coverage [4]; however, efforts to reduce vaccine-preventable deaths may be hin-
dered further in malaria-endemic regions where it has long been suspected that Plasmodium
falciparum infection reduces vaccine efficacy in children [5].
Most licensed vaccines confer protection through antibodies [6]. Long-lived antibody re-
sponses depend on memory B cells (MBCs) and long-lived plasma cells (LLPCs) [7]. LLPCs re-
side in the bone marrow and constitutively secrete antibodies, whereas MBCs mediate recall
responses after antigen re-exposure by differentiating into antibody-secreting cells (ASCs). Al-
though heterogeneity exists in the longevity of antibody responses following infection or vacci-
nation, in general, antibody responses are long-lived. For example, half-life estimates of IgG
responses in adults range from 11 years for the tetanus vaccine to 3014 years for the measles
vaccine [8].
In contrast, antibody responses to P. falciparum infection are relatively short-lived, particu-
larly in children [9], which likely contributes to the inefficient acquisition of clinical immunity
to malaria [10]. Mounting evidence suggests that Plasmodium blood-stage infection is associat-
ed with dysregulated B cell and CD4+ helper T cell function and that this contributes to short-
lived antibody responses to malaria [11–14]. What remains unknown is whether antibody lev-
els induced by prior vaccinations are adversely affected by P. falciparum infections—a scenario
that would dictate re-evaluation of policies regarding re-immunization frequency in malaria-
endemic areas.
Interestingly, a recent study in mice suggested that Plasmodium blood-stage infection is del-
eterious to pre-existing levels of heterologous antibodies. Specifically, Ng et al. showed that
Plasmodium chaubaudi (Pcc) blood-stage infection of influenza-immune B6 mice resulted in a
transient drop in influenza-specific antibodies and ASCs in bone marrow that, paradoxically,
recovered ~21 days post Pcc infection [15]. Given the potential public health implications of
even transient declines in antibodies to common childhood vaccines, we sought to determine
whether findings in the Pccmodel are generalizable to other Plasmodium species in mice of di-
verse genetic backgrounds and, of clinical relevance, whether acute malaria in children is asso-
ciated with a decrease in levels of pre-existing antibodies to vaccines.
Materials and Methods
Mice
BALB/c and C57BL/6 mice (NCI, Frederick, MD) and Swiss Webster mice (Harlan Laborato-
ries) were housed at the University of Iowa. Female mice were used to initiate experiments at
8–12 weeks of age. Euthanasia was carried out by cervical dislocation. Mouse experiments were
approved by The University of Iowa Animal Care and Use Committee.
Immunizations. SRBC immunization: 5 ml of Sheep blood (Colorado Serum Company,
Denver, CO) was washed twice with Gibco PBS (Life Technologies). Red blood cells (RBCs)
were pelleted at 1000 rpm for 10 min and the volume of the cell pellet measured. One volume
of pellet was resuspended in 9 volumes PBS to prepare 10% SRBC suspension. 200 μl of the
10% SRBC suspension was injected intraperitoneally. Influenza virus immunization: Stock A/
37/PR/8 (PR8) with TCID titers of 1011 /ml were diluted with PBS to 1:200,000 and 50 μl of
viral suspension was given intranasally to anesthetized mice.
Infections and chloroquine treatment. Cryopreserved P. yoelii (Py) 17XNL infected
RBCs were diluted with saline such that mice were intravenously injected with 100,000 P. yoelii
(Py)-infected RBCs at the time indicated relative to immunization with SRBC or IAV. Parasite-
mia was monitored by Giemsa stained blood smears. In the indicated experiments, mice were
treated on day 4 post infection and every second day thereafter by intraperitoneal injection
with 50 mg/kg of chloroquine to prevent high parasite burden. Parasitemia in chlorquine-
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treated mice did not exceed 4% at any time point during the infection. Listeria monocytogenes
(DPL-1942) was appropriately diluted and 5 x 105 cfu were injected intravenously. LCMV
Armstrong was appropriately diluted and 2 x 105 pfu injected intraperitoneally. For challenge
studies, PR8 stock virus was diluted 1:20,000 and mice were infected intranasally.
Hemagglutination antibody titer assay. Serum samples obtained at the indicated days
relative to immunization or infection were serially diluted in PBS and mixed 1:1 with a 1% sus-
pension of SRBC in triplicate in round-bottom 96-well plates. Plates were mixed and incubated
at 4°C for 60 minutes then observed for hemagglutination. Hemagglutinin antibody titers are
the highest dilution of serum with a positive result. Titers are expressed as logarithms to base 2
(log2).
Virus neutralizing antibody titers. Sera obtained at indicated days relative to immuniza-
tion and infection were serially diluted in DMEM and 60 μl of each dilution (in triplicate) was
mixed with equal volume containing 1000 TCID50 PR8 in a round-bottomed 96-well plate and
incubated at 4°C for 20 minutes. 100 μl of this mixture was added to 96-well flat bottom plates
containing 1 x 105 MDCK cells per well. Plates were incubated for 24 hours in a tissue culture
CO2 incubator, medium was replaced with 200 μl of DMEM containing 10% FCS, 0.002%
Trypsin and incubated for 72 hours. To determine neutralizing titers, 100 μl of supernatant
was mixed with equal volume of 1% chicken RBC suspension, incubated at 4°C for 30 minutes
and observed for hemaagglutination as described above. The highest dilution of serum that
neutralizes the virus and thus shows no agglutination is the neutralizing titer. Titers are ex-
pressed logarithms to base 2 (log2).
Virus burden in lungs. On day three post-challenge infection with PR8, lungs were ho-
mogenized in DMEM and stored at −80°C until use. Samples were thawed and virus levels de-
termined as above.
Plasma cell Apoptosis, BAFF-R expression and BAFF level determination. Plasma cells
in the spleen and bone marrow were identified with the indicated antibodies as CD45.2+ (104),
B220+ (6B2), CD19+ (6D5), IgD- (11-26c.2a), CD138+ (281–2). Apoptosis in plasma cells was
determined by detection of active Caspase-3/7 using the VybrantFAMCaspase-3 and Caspase-
7 Assay Kit (Invitrogen) according to manufacturer’s protocol. BAFF receptor (R) expression
was detected on CD45.2+B220+CD19+IgD-CD138+ cells by staining with anti-BAFF-R mAb
(11C1). Serum BAFF levels were quantified by ELISA according to manufacturer’s protocol
(R&D Systems).
Ethical approval for Mali study. The Ethics Committee of the Faculty of Medicine, Phar-
macy and Dentistry at the University of Sciences, Technique and Technology of Bamako, and
the NIAID/NIH IRB approved this study. Written informed consent was obtained from pa-
rents or guardians of participating children.
Mali study
The field study was conducted in Kalifabougou, Mali where P. falciparum transmission occurs
annually (June-December). The cohort was described in detail elsewhere [10]. Here, we identi-
fied 54 children aged 2–5 years not infected with P. falciparum (by PCR) in May 2012 who had
plasma available before (January 2012) and after (May 2012) the 6-month dry season, 10 days
after the first malaria episode of the ensuing 6-month malaria season (variable date) and after
the subsequent dry season (May 2013). Malaria was defined as2,500 asexual parasites/μL, ax-
illary temperature37.5°C and no other cause of fever by exam. Malaria was detected by pas-
sive and weekly active surveillance. Individuals with malaria symptoms and any parasitemia
were treated according to Malian National Malaria Control Program guidelines. Blood was
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drawn by venipuncture into sodium citrate–containing Vacutainer tubes (BD) and plasma sep-
arated and cryopreserved.
P. falciparum detection. Thick blood smears stained with Giemsa were counted against
300 leukocytes. Densities were recorded as the number of asexual parasites/microliter blood
based on a mean leukocyte count of 7500 cells/μL. P. falciparum PCR methods were described
previously [10].
ELISA human samples. IgG specific for tetanus toxoid, measles and Hepatitis B surface
antigen was measured using ELISA kits according to manufacturer’s instructions (Alpha Diag-
nostic, San Antonio, TX). Plasma diluted 1:100 was analyzed in duplicate on single plates for
each vaccine-specific ELISA. IgG concentrations were calculated by fitting to standard curves
generated from standards in each kit and expressed as Units/milliliter.
Statistical analysis
Mouse data were analyzed with two-tailed unpaired Student’s t-test using GraphPad Prism
software. Humans ELISA data were log-transformed (with base 10). The Wilcoxon rank-sum
test was used to compare slopes. Linear mixed-effects models compared rates of change during
periods of malaria exposure and non-exposure, where the random intercept accounted for cor-
relations among data points (before and after dry season, and 10 days after treatment) and
fixed effects included time from enrollment and the minimum of 0 and time since end of dry
season. Half-lives of IgG levels were estimated by fitting a linear mixed-effects model with
three data points: before and after first dry season, and after second dry season, where random
intercept accounted for within-subject correlation, and age at visit as fixed effect. IgG half-lives
were estimated by the ratio of log10 (1/2) and fixed-effect slope of age; 95% CIs were obtained
by similar calculations using endpoints of the 95% CI of fixed-effect slopes. Statistical signifi-
cance was defined as 2-tailed P value<0.05. Analyses were performed in R v.2.15.1 (http://
www.R-project.org) or Prism 5.0d (GraphPad).
Results
Plasmodium infection compromises antibody responses to third party
antigens
Multiple studies report atypical MBCs and relatively poor antibody responses in children living
in malaria endemic regions [11]. However, it remains unknown if these aberrant responses are
dictated at early or late time points during chronic Plasmodium infection and whether they re-
flect malaria-specific or generalized immune system abnormalities. To address this, we immu-
nized BALB/c mice with Sheep Red Blood Cells (SRBC), then infected some mice in each
group two days later with 105 P. yoelii (Py) 17XNL parasitized red blood cells (pRBC) (Fig 1A).
This experiment was designed to mimic natural infection, which is restricted to asymptomatic
liver stage for ~44 hours in Py sporozoite-infected mice and is followed by blood-stage infec-
tion. SRBC-specific IgG titers were then determined at ~weekly intervals. This experiment re-
vealed that anti-SRBC titers in control and Py-infected mice were similar at day 8 post-
immunization (6 days post-infection), however, while titers continued to rise in control mice
and stabilized by ~30 days post-immunization, anti-SRBC titers in Py-infected mice decreased
over ~2 weeks before stabilizing for the 90-day evaluation period (Fig 1B). Importantly, replac-
ing Py with bacterial (Listeria monocytogenes) or viral (lymphocytic choriomeningitis virus) in-
fections did not compromise anti-SRBC antibody responses (Fig 1C). Thus, the failure to
complete the normal antibody response to SRBC was not a general feature of infection.
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Additionally, treatment of mice with sub-clearing doses of the anti-malarial drug chloroquine
(beginning 4 days post-infection and every 3 days following initial inoculation) limited infec-
tion (blood-stage parasitemia remained<4% for the entire experiment, data not shown) but
did not prevent the Py associated drop in antibody titers (Fig 1D). Of note, similar data were
generated in inbred C57BL/6 (B6) and outbred Swiss Webster mice (not shown). Thus, Py
Fig 1. Decrease of SRBC-specific antibody responses after P. yoelii infection. A: Experimental design. Female BALB/c mice were immunized with 10%
SRBC suspension intraperitoneally. Two days later, half of these mice were infected with 105 P. yoelii infected RBCs intravenously, while the other half of
mice were injected with saline. Serum samples were collected on specific days and analyzed for Heamagglutination titers.B: Heamagglutination titers over a
period of 90 days in mice immunized with SRBC and infected or not infected with P.yoelii. C: SRBC immunized mice were injected with saline or infected after
two days with P. yoelii, L.monocytogenes (5 X 106 cfu) or LCMV (2 X 105 pfu) and Heamagglutination titers were analyzed over a period of 30 days.D:
SRBC immunized mice were injected with saline or infected after two days with P. yoelii. Some P. yoelii infected mice received chloroquine (50 mg per kg) on
days 4, 7, 10, 12 and 15 post infection to limit blood stage parasitemia and Heamagglutination titers were analyzed over a period of 30 days. Parasitemia did
not exceed 4% in the chloroquine treated mice. The data are representative of two or more independent experiments with10 mice per group/exp. *p<0.05,
**p<0.01, ***p<0.001.
doi:10.1371/journal.pone.0125090.g001
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blood-stage infection rapidly and specifically impairs the evolution of antibody responses to a
third-party antigen, in both inbred and outbred mice, and this does not require sustained high-
level parasitemia.
Plasmodium infection decreases pre-existing antibody titers and
compromises immunity
A recent study showed that Pcc blood-stage infection of influenza virus-immune B6 mice re-
sulted in a transient drop in circulating antibody levels and ASCs in bone marrow that, para-
doxically, recovered by ~21 days post-infection [15]. To determine if this finding is
generalizable to Py infection in a genetically diverse host, outbred Swiss Webster mice were im-
munized with SRBC and SRBC-specific antibody titers were determined until stable titers were
observed (>40 days). On day 46 post-SRBC, some mice were infected with Py pRBC. Again,
antibody titers fell sharply over the ensuing 2 weeks before stabilizing in Py-infected mice,
whereas no drop in antibody titers was observed in control mice (Fig 2B). These data show that
blood-stage Py infection also compromises stable antibody responses maintained by LLPCs.
To extend these data to antibody responses against a pathogen and to compare with the pub-
lished data on Pcc in B6 mice, outbred Swiss Webster mice were sublethally infected with the
mouse adapted H1N1 influenza A virus (IAV) A/PR/8 (PR8). At day 40 post-infection, when
PR8-specific neutralizing antibody titers had been stable for several weeks, some mice were in-
fected with Py pRBC (Fig 2A). Strikingly, we observed a substantial decline in circulating IAV-
specific neutralizing antibodies (Fig 2C) over the next two weeks, followed by stable mainte-
nance at reduced amounts for at least 35 days post Py infection. Of note, analyses of IAV-spe-
cific ASCs in the bone marrow 7 days after infection revealed a significant decrease in mice
that had received Py blood-stage infection (Fig 2D). To determine the biological import of de-
creased IAV-neutralizing antibodies, naïve, IAV-immune and IAV-immune/Py-infected mice
were challenged with PR8 and virus titers in the lung (Fig 2E) and mortality (Fig 2F) were eval-
uated. As expected, naïve mice had high virus titers and ~50% mortality whereas control IAV-
immune mice had virus titers in the lungs below the limit of detection and exhibited no mortal-
ity. In contrast, IAV-immune mice with diminished antibody responses due to Py infection ex-
hibited substantial virus titers in the lung and ~40% mortality after homologous IAV
challenge. These data reveal that the Py associated drop in long-term antibody titers has a pro-
found impact on the ability of an immune host to resist subsequent infections.
Of note, evaluation of splenic CD138+ plasma cells in SRBC-immunized mice with and
without blood-stage Py infection revealed no changes in total cell numbers in the spleen, how-
ever, there was a substantial increase in the total numbers of plasma cells that exhibited signa-
tures of apoptosis (active caspase 3/7) (Fig 3A and 3B). BAFF-receptor (BAFF-R) signals
promote survival of antibody secreting plasma cells [16] and BAFF levels have been shown to
be elevated in children with malaria (28). Influenza immune mice (day 42 p.i.) were mock in-
fected or infected with Py and BAFF-R expression on plasma cells and circulating BAFF levels
were analyzed six days later. We observed decreased numbers of BAFF-R expressing CD138+
plasma cells in spleen and bone marrow (Fig 3C and 3D) of Py infected mice. In addition, we
observed increased amounts of BAFF in the serum (Fig 3E). The loss of BAFF-R may contrib-
ute to decreased survival of plasma cells observed with Py infection and explain the elevated
BAFF levels in the circulation.
Although antibody titers were decreased by Py infection, they were not eliminated. To de-
termine if compromised antibody response also eliminated MBCs, SRBC-immune mice that
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Fig 2. Decrease of preexisting antibodies after P. yoelii infection. A: Experimental design. BALB/c mice and outbred SwissWebster mice were
immunized with SRBC or received sublethal intranasal infection with PR8 IAV. At the indicated days post infection, some mice were infected with P. yoelii.
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were infected or not with Py were subjected to booster immunization with SRBC (Fig 4). Boost-
ing led to a similar fold-increase in SRBC-specific titers and responses occurred with similar ki-
netics in both groups of mice. These data suggest that MBC responses to SRBC were largely
intact in mice that had been infected with Py blood-stage parasites and could be successfully re-
called by booster immunization.
Impact of malaria on pre-existing antibodies to vaccines in children
Together, the observations in mouse models prompted us to investigate the impact of acute
malaria on pre-existing antibodies to common vaccines in children. In a longitudinal study in
Mali of 54 children aged 2–5 years (mean 3.5 years), we took advantage of the sharply demar-
cated 6-month rainy season (intense malaria) and 6-month dry season (negligible malaria)
[10] (Fig 5A) to compare kinetics of vaccine-specific IgG levels in the presence and absence of
malaria exposure. We measured IgG levels to vaccines given to Malian children in the first year
of life including tetanus, measles and hepatitis B [17–19]. In Mali, tetanus and hepatitis B vac-
cines are given at 6, 10 and 14 weeks of age, and the measles vaccine at 9 months [20]. Vaccine-
specific IgG was measured at four time points over 18 months: before and after the dry season;
10 days after treatment of the first malaria episode of the ensuing malaria season; and after the
subsequent dry season (Fig 5B).
Subjects were asymptomatic and uninfected (by P. falciparum PCR) at the end of the first
dry season. The median time between the end of the first dry season and the first malaria epi-
sode was 107 days (IQR 65 days). At the first malaria episode children had an average tempera-
ture of 38.4°C (range 37.5–40.3), were infected with P. falciparum (geometric mean: 33,688
asexual parasites/μl of blood, 95% CI 23,283–47,832) and had no other cause of fever on exami-
nation. Malaria was treated with a standard course of artemether/lumefantrine. Demographic/
clinical data of subjects are shown in Table 1.
To test the hypothesis that acute malaria accelerates the loss of pre-existing vaccine-specific
IgG levels we compared the rate of change in IgG levels during the dry season to the rate of
change from the end of the same dry season to 10 days after treatment of the first malaria epi-
sode of the ensuing malaria season (Fig 5B). IgG levels ten days post-malaria were measured
because mouse models showed heterologous IgG titers fall within 2 weeks of Plasmodium in-
fection (Fig 2B). At the population level, the average IgG level slope either remained unchanged
(hepatitis B and tetanus) or increased following malaria (measles) relative to average IgG level
slopes during the preceding dry season (Table 2); and reassuringly, IgG levels remained above
protective thresholds in most children (Table 2). However, at the individual level, malaria was
associated with an accelerated decline in vaccine-specific IgG levels in some children, relative
to each child’s rate of decline during the preceding dry season (Fig 5C–5E). Specifically, malaria
was associated with accelerated declines in IgG specific for tetanus, measles and hepatitis B in
53%, 19% and 33% of children, respectively (Fig 5C–5E). Multivariate analysis revealed a
Serum samples collected on specific days were analyzed for Heamagglutination titers or virus neutralizing antibody titers.B: Heamagglutination titers over a
period of 95 days post SRBC immunization in P. yoelii infected and uninfected mice. C: Virus neutralizing antibody titers over a period of 75 days post PR8
infection in mice and infected or not infected with P.yoelii. D: PR8 specific Antibody secreting cells in the bone marrow of immune mice seven days after
saline or P. yoelii infection. The numbers are derived from combination of one tibia and one femur from each mousse. E: Naïve or PR8 immune mice
receiving saline or P. yoelii were challenged with PR8 virus 40 days post P.yoelii infection. On day 3 post challenge, lungs were harvested to determine virus
load., each symbol represents an individual mouse. F: Survival curve of mice as in E. Data are representative of three independent experiments with 8 to 12
mice per group/experiment. * p<0.05, ** p<0.01, *** p<0.001.
doi:10.1371/journal.pone.0125090.g002
Malaria Impact on Pre-Existing Antibody to Viral and Vaccine Antigens
PLOS ONE | DOI:10.1371/journal.pone.0125090 April 28, 2015 8 / 15
marginally significant relationship between higher temperature at the time of malaria and the
risk of accelerated declines in IgG specific for measles (p = 0.07), hepatitis B (p = 0.06) and teta-
nus (p = 0.07) after adjusting for age, gender, and parasitemia.
In light of these findings, and given that children in this region experience up to 5 malaria
episodes/season [24], we performed exploratory analyses to estimate vaccine-specific IgG half-
lives using data from three time points: before and after the first dry season, and after the
Fig 3. P. yoelii infection increases plasma cell apoptosis, decreases plasma cell BAFF-R and increases circulating BAFF concentrations. BALB/c
mice were immunized with 10% SRBC suspension. Two days later, half of these mice were infected with 106 P. yoelii parasitized RBC while the other half of
mice were injected with saline. (A) Total plasma cells in the spleen at day 13 post SRBC immunization. (B) Total caspase 3/7 positive plasma cells in the
spleen at day 13 post SRBC immunization. Data in A,B are mean + S.D. and represent one of two independent experiments with 5 mice per group. Swiss
Webster mice were infected with a sublethal dose of PR8. Forty-two days later, half of these mice were infected with 106 P. yoelii parasitized RBC. The
percent of BAFF-R positive plasma cells in the (C) spleen and (D) bone marrow were determined on day forty-eight after immunization (day 6 after Py
infection). Serum was obtained frommice in C,D and analyzed for circulating BAFF concentrations (E). Data in C-E reflect mean + S.D. and represent one of
two independent experiments with 5 mice per group. *** p<0.001, ** p<0.01, * p<0.05, ns p non-significant
doi:10.1371/journal.pone.0125090.g003
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second dry season (Fig 5B). The mean half-life of IgG levels for tetanus was 0.89 years (95% CI,
0.70–1.21), measles 2.02 years (95% CI, 1.57–2.83) and hepatitis B 6.96 years (95% CI, 4.60–
14.33) (Table 3; Fig 5C–5E). Since previous studies showed that antibody responses do not
reach steady-state levels until 3–4 years after vaccination [8, 25, 26] we estimated IgG half-lives
separately for children aged 2–3 years or 4–5 years at study entry, the latter providing a closer
approximation of steady-state levels (~3–4 years post-vaccination). As expected, IgG half-life
estimates were greater in older children—tetanus 0.98 years (95% CI, 0.78–1.34), measles 2.56
years (95% CI, 1.74–4.91) and hepatitis B 9.41 years (95% CI, 5.15–54.31) (Table 3; Fig 5C–
5E).
Discussion
Here we provide evidence in mice and some children that Plasmodium infection is associated
with an accelerated loss of pre-existing viral and vaccine-specific antibodies. We extend the re-
cent study of Ng et al. with the Pccmodel [15] and describe marked and sustained decreases in
antibody levels in Py-infected inbred and outbred mice. Reassuringly, population-averaged IgG
levels to tetanus, measles and hepatitis B in children did not decrease with acute malaria and
remained above protective thresholds in most children during the study period. However, pop-
ulation-averaged data obscures the observation that acute malaria was associated with acceler-
ated losses of vaccine-specific IgG in some children, particularly for tetanus, which may have
public health implications. Indeed, a recent report fromMali (<60km from study site) indicat-
ed that 6.5% of hospital admissions were for tetanus with a mortality rate of 46.2% [27]. More-
over, exploratory analyses yielded half-life estimates of IgG specific for tetanus (0.98 years) and
measles (2.56 years) that were considerably shorter than estimates reported in a study of U.S.
adults (tetanus: 11 years; measles: 3014 years) [8], further suggesting that chronic malaria expo-
sure and associated factors (co-infection, malnutrition) may accelerate the loss of vaccine-spe-
cific antibodies. As expected, we found that vaccine-specific IgG half-life estimates were greater
Fig 4. P. yoelli infection does not disrupt the anamnestic response to SRBC immunization. BALB/c
mice were immunized with 10% SRBC suspension. Two days later, half of these mice were infected with 106
P. yoelii while the other half of mice were injected with saline. A booster dose of 10% SRBC suspension was
given after 40+ days to both groups of mice. Serum samples were collected on the indicated days and
analyzed for Heamagglutinin antibody titers. Data are representative of two experiments, with 10 mice per
group/exp. *** p<0.001, ** p<0.01, * p<0.05, ns p non-significant.
doi:10.1371/journal.pone.0125090.g004
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in older children who were immunized 3–4 years before this study—a point at which antibody
decay rates approach steady-state [25, 26]. However, it remains possible that the steady-state
had not been reached in these children and additional studies are needed to resolve this.
Mice used in this study were malaria-naïve, whereas children had already experienced 2–5
malaria seasons; therefore, it remains possible that P. falciparum infections earlier in life would
accelerate the loss of vaccine-specific IgG in more children and to a greater degree than ob-
served here. Controlled human malaria infections [28] could determine the impact of first P.
falciparum infections on pre-existing levels of vaccine-specific antibodies.
Amanna et al. found that smallpox vaccination (vaccinia virus infection) in humans did not
significantly alter levels of pre-existing IgG to unrelated antigens, including tetanus and mea-
sles [29], suggesting that the accelerated declines in vaccine-specific IgG observed in associa-
tion with acute malaria in this study may be specific to Plasmodium rather than a general
feature of infection. Accordingly, we did not detect a decline in IgG to unrelated antigens in
mice after infection with Listeria monocytogenes or LCMV (Fig 1B).
The mechanisms by which Plasmodium accelerates the decline of IgG to unrelated antigens
remains unclear. It has been suggested that binding of Plasmodium-infected erythrocytes to
bone marrow stromal cells may disrupt LLPC survival signals [30, 31]. Additionally, we find
that BAFF receptor expression is downmodulated on splenic and bone marrow plasma cells
and circulating BAFF levels increase in Py-infected mice (Fig 3), the latter is a phenomenon
also observed in human malaria [32]. The recent study with Pcc suggested that Plasmodium-
Fig 5. Kinetics of vaccine-specific IgG levels in children during the dry season and after acute malaria. (A) The study was designed to take advantage
of the sharply demarcated and intense 6-month malaria season (July—December) and 6-month dry season (January—June; negligible malaria
transmission) in Mali. Shown is the number of febrile malaria episodes per day over two years at the study site in a cohort of 695 children and adults. (B) IgG
levels specific for routine vaccines administered under one year of age (tetanus, measles and Hepatitis B) were measured in plasma collected from 54
children at four time points (vertical arrows): before and after the 6-month dry season, 10 days after the first acute malaria episode of the ensuing malaria
season, and after the second dry season. Shown for each subject are IgG titers specific for (C) tetanus, (D)measles and (E) hepatitis B vaccines at the time
points indicated in (B). The x-axis indicates the age at which the respective time points occurred for each subject. In red are subjects who experienced an
accelerated decline in vaccine-specific IgG titers following acute malaria (between 2nd and 3rd time points) relative to each child’s own rate of change during
the preceding dry season (between 1st and 2nd time points). The percentage of subjects for whommalaria was associated with an accelerated decline in IgG
is shown in red text for each vaccine. A linear mixed effects model that included three time points over 18 months (before and after the first dry season, and
after the second dry season) was used to estimate average IgG half-lives for all subjects (black dashed line) and separately for children aged3 years
(green dotted line) and >3 years of age (blue dash-dot line).
doi:10.1371/journal.pone.0125090.g005
Table 1. Demographic and clinical characteristics of study subjects.
Variable Subjects (n = 54)
Gender, % female (no.) 43 (23)
Age, years [mean (range)] 3.5 (2–5)
Time to first malaria episode, days [median (IQR1)] 2,3 107 (65)
Axillary temperature at first malaria episode, °C, [mean (range)] 38.4 (37.5–40.3)





2Malaria episode defined as T37.5°C, asexual parasitemia 2500/microliter and no other cause of fever
discernible on physical examination.
3Days since enrollment during a cross-sectional survey before the malaria season in May 2012.
495% confidence interval.
doi:10.1371/journal.pone.0125090.t001
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induced polyclonal B cell activation and the attending hypergammaglobulinemia resulted in
apoptosis of LLPC through a CD32-dependent mechanism (21). Consistent with this, we ob-
served substantial increases in apoptotic plasma cells in the bone marrow of mice after Py in-
fection (Fig 3). Thus, the decline in LLPCs observed in mice after Plasmodium infection may
be multifactorial.
We observed that acute malaria is associated with a transient increase in vaccine-specific
IgG in some children. It is possible that bystander proliferation and differentiation of vaccine-
specific MBCs into ASCs [33] masked the loss of vaccine-specific LLPCs in some children.
This is supported by prior observations that acute malaria is associated with modest increases
in tetanus-specific MBCs [34], and by in vitro studies that implicate the cysteine-rich interdo-
main regions 1α of the P. falciparum erythrocyte membrane protein 1 (PfEMP1) as a T cell–in-
dependent polyclonal B cell activator [35]. The factors underlying net increases or decreases in
antibody levels to unrelated antigens during acute malaria in children are unclear. We found a
marginally significant association between higher temperature during malaria and declines in
IgG to tetanus, measles and hepatitis B; whereas age, gender and parasitemia had no effect. Ad-
ditional studies may illuminate other factors underlying the variable effects of malaria on pre-
existing heterologous antibodies.
Approximately 3.4 billion people in 97 countries are at risk of malaria [36]. Here we provide
evidence that acute malaria is associated with an accelerated loss of pre-existing viral and vac-
cine-specific IgG in mice and some children. Given the enormous burden of malaria world-
wide, even modest malaria-associated declines in vaccine-specific antibodies in a fraction of
the population could contribute to the high incidence of vaccine-preventable diseases. Further
studies are needed to investigate the generalizability of these findings and their potential impli-
cations for vaccine policies in malaria-endemic countries.






Subjects with protective IgG
titer, no. (%)1
Dry season slope, log 10 unit/
year (SE2)




Tetanus 0.01 IU/mL [21] 54 (100) -0.247 (0.054)4 -0.394 (0.091) 4 0.48
Measles 0.2 IU/mL [22] 54 (100) -0.125 (0.052) 4 0.288 (0.087) 4 0.003
Hepatitis B 10 mIU/mL [23] 52 (96) -0.037 (0.023) 0.229 (0.122) 0.35
1Results based on the last time point of the study period.
2Standard error.
3p value for the difference in slopes between the dry season and period of malaria exposure was obtained by fitting a linear mixed effects model.
4Indicates that the slope is significantly different than zero.
doi:10.1371/journal.pone.0125090.t002
Table 3. Half-life estimates of vaccine-specific IgG levels overall and by age group.
VaccineV Vaccine All Age  3 years Age > 3 years
Slope1 (SE2) T ½
3,years Slope (SE) T ½, years Slope (SE) T ½, years
Tetanus -0.34 (0.05) 0.89 (0.70, 1.21) -0.45 (0.10) 0.66 (0.47, 1.14) -0.31 (0.04) 0.98 (0.78, 1.34)
Measles -0.15 (0.02) 2.02 (1.57, 2.83) -0.17 (0.03) 1.76 (1.26, 2.90) -0.12 (0.03) 2.56 (1.74, 4.91)
Hepatitis B -0.04 (0.01) 6.96 (4.60, 14.33) -0.07 (0.02) 4.07 (2.62, 9.17) -0.03 (0.01) 9.41 (5.15, 54.31)
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